Search

Your search keyword '"L, Lanfrancone"' showing total 115 results

Search Constraints

Start Over You searched for: Author "L, Lanfrancone" Remove constraint Author: "L, Lanfrancone"
115 results on '"L, Lanfrancone"'

Search Results

1. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma

2. Bombesin-induced pancreatic regeneration in pigs is mediated by p46Shc/p52Shc and p42/p44 mitogen-activated protein kinase upregulation

Catalog

Books, media, physical & digital resources

3. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein

4. Shc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8

5. Modified phage peptide libraries as a tool to study specificity of phosphorylation and recognition of tyrosine containing peptides

6. Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation

7. Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase

8. Constitutive phosphorylation of Shc proteins in human tumors

9. Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/SoS and Grb2/p140 complexes to the beta receptor subunit

10. IX Eular Workshop for Rheumatology Research

12. Early tolerance and late persistence as alternative drug responses in cancer.

14. Structural Insights on the Role of Halogen Bonding in Protein MEK Kinase-Inhibitor Complexes.

15. Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion.

16. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.

17. Actionable Genetic Screens Unveil Targeting of AURKA, MEK, and Fatty Acid Metabolism as an Alternative Therapeutic Approach for Advanced Melanoma.

18. BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting.

19. TFEB and TFE3 drive kidney cystogenesis and tumorigenesis.

20. Epigenetically regulated PCDHB15 impairs aggressiveness of metastatic melanoma cells.

21. Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma.

22. DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness.

23. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors.

24. Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process.

25. Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation.

26. ShcD Binds DOCK4, Promotes Ameboid Motility and Metastasis Dissemination, Predicting Poor Prognosis in Melanoma.

27. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells.

28. Modeling cell proliferation in human acute myeloid leukemia xenografts.

29. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.

30. Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.

31. The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2 + breast cancer cells.

32. p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.

33. Interrogating open issues in cancer medicine with patient-derived xenografts.

34. Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth.

35. Interrogating open issues in cancer precision medicine with patient-derived xenografts.

36. Dual modulation of MCL-1 and mTOR determines the response to sunitinib.

37. RNAi screens identify CHD4 as an essential gene in breast cancer growth.

38. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.

39. In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

40. Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner.

42. Molecular networks in melanoma invasion and metastasis.

43. Cellular heterogeneity during embryonic stem cell differentiation to epiblast stem cells is revealed by the ShcD/RaLP adaptor protein.

44. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.

45. Pirin inhibits cellular senescence in melanocytic cells.

46. Pirin delocalization in melanoma progression identified by high content immuno-detection based approaches.

47. Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells.

48. Melanoma: targeting signaling pathways and RaLP.

49. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness.

50. The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity.